Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Shinichiro Takahashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4828-3965; OpenAlex author ID A5091260536. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
92
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 22

  1. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  2. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  3. Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma. Co-author PMID 40105230↗
  4. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  5. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  6. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocar… First author DOI 10.5009/gnl220311↗
  7. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  8. Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.3892/or.2022.8332↗
  9. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Co-author DOI 10.1111/cas.14914↗
  10. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Co-author DOI 10.1038/s41598-020-74067-z↗
  11. Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001539↗
  12. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001547↗
  13. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  14. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-019-53801-2↗
  15. How to treat borderline resectable pancreatic cancer: current challenges and future directions. Co-author DOI 10.1093/jjco/hyx191↗
  16. Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. Co-author DOI 10.1097/mpa.0000000000001106↗
  17. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, pr… Co-author DOI 10.1136/bmjopen-2017-018445↗
  18. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.12.362↗
  19. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global ra… Co-author DOI 10.1093/jjco/hyv011↗
  20. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  21. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  22. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. Co-author DOI 10.1007/s00534-011-0371-z↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Motohiro Kojima · 9 shared papers, 2017–2022 · strength 0.94
  2. Hirochika Toyama · 6 shared papers, 2019–2026 · strength 0.82
  3. Soichiro Morinaga · 6 shared papers, 2019–2024 · strength 0.73
  4. Naoto Gotohda · 7 shared papers, 2011–2022 · strength 0.69
  5. Katsuhiko Uesaka · 6 shared papers, 2017–2023 · strength 0.65
  6. Ippei Matsumoto · 3 shared papers, 2023–2026 · strength 0.56
  7. Toshio Nakagohri · 2 shared papers, 2023–2025 · strength 0.47
  8. Shigenori Ei · 2 shared papers, 2023–2025 · strength 0.47
  9. Taro Mashiko · 2 shared papers, 2023–2025 · strength 0.47
  10. Shin Kobayashi · 4 shared papers, 2018–2022 · strength 0.46
  11. Motokazu Sugimoto · 4 shared papers, 2018–2022 · strength 0.46
  12. Masafumi Ikeda · 6 shared papers, 2011–2022 · strength 0.46
  13. Sohei Satoi · 3 shared papers, 2013–2026 · strength 0.43
  14. Satoshi Hirano · 3 shared papers, 2013–2023 · strength 0.30
  15. Keita Wada · 2 shared papers, 2013–2026 · strength 0.28
  16. Masayuki Sho · 2 shared papers, 2013–2026 · strength 0.28
  17. Tomoo Kosuge · 2 shared papers, 2012–2026 · strength 0.28
  18. Masaki Mori · 1 shared paper, 2025 · strength 0.26
  19. Horacio Cabral · 2 shared papers, 2020–2022 · strength 0.25
  20. Masashi Kudo · 2 shared papers, 2020–2022 · strength 0.25
  21. Hideki Ueno · 1 shared paper, 2026 · strength 0.25
  22. Hideyuki Yoshitomi · 1 shared paper, 2026 · strength 0.25
  23. Michiaki Unno · 1 shared paper, 2026 · strength 0.25
  24. Tsutomu Fujii · 1 shared paper, 2026 · strength 0.25
  25. Fuyuhiko Motoi · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.